Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Completed · Phase 1

Conditions studied: Recurrent Glioblastoma, Brain Tumor

In brief

This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.

Key facts

Study ID

NCT00503204

Run by

AstraZeneca

People needed

20

Starts

2007-09-01

Expected to finish

2008-12-01

Last updated by the study team

2009-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary recurrent malignant brain tumour for whom lomustine would be standard therapy - diagnosis \& stage
• Patients received no more than 2 previous systemic chemotherapy regimes
• Life Expectancy > 12 weeks
• Patients must be at least 3 months from the completion of cranial radiation therapy

You may not qualify if…

• History of poorly controlled high blood pressure
• Recent major surgery prior to entry into the study

Where it is running

• Research Site — Boston, Massachusetts, United States
• Research Site — Sutton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.